The principal objective of the Clinical Core is to enroll and longitudinally follow a panel of volunteer subjected willing to participate in annual evaluations, in clinical research project and willing to give autopsy consent. The panel will consist of over 265 subjects with dementia, primarily Alzheimer's Disease (AD); 150 age, sex and education matched ambulatory and cognitively normal control subjects; including volunteers with proven family history of AD and a small group of medically impaired controls. A Satellite in Imperial County, California, follows 100 primarily AD Hispanic patients and controls. We propose to extend our Hispanic Initiative to South San Diego, where we will follow an additional 100 Hispanic subjects. The annual evaluations will include demographic, historical, medical neurological, psychiatric, and neuropsychological examination. These evaluations aid in the diagnoses, in tracking yearly changes in cognitive and neurological progression. The evaluations provide a behavioral data base that can be used by the various research projects associated with the ADRC and in addition provide detailed longitudinal data on the course and progression of AD. The Clinical Core maintains banks of fibroblast cultures, whole blood, serum samples, and CSF that may be used by a variety of investigators. The Clinical Core provides the resource that permits participation of the ADRC in CERAD and other registries and in multi- center therapeutic trials. The Clinical Core provides training, comparative data, and assistance with design and interpretation of cross- cultural studies of dementia, with ongoing studies in Rancho Bernado, California, Shanghai, China and Kuopio, Finland.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005131-12
Application #
3726256
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Young, Jessica E; Fong, Lauren K; Frankowski, Harald et al. (2018) Stabilizing the Retromer Complex in a Human Stem Cell Model of Alzheimer's Disease Reduces TAU Phosphorylation Independently of Amyloid Precursor Protein. Stem Cell Reports 10:1046-1058
Golde, Todd E; DeKosky, Steven T; Galasko, Douglas (2018) Alzheimer's disease: The right drug, the right time. Science 362:1250-1251
Reas, Emilie T; Hagler Jr, Donald J; White, Nathan S et al. (2018) Microstructural brain changes track cognitive decline in mild cognitive impairment. Neuroimage Clin 20:883-891
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Graves, Lisa V; Holden, Heather M; Van Etten, Emily J et al. (2018) New Yes/No Recognition Memory Analysis on the California Verbal Learning Test-3: Clinical Utility in Alzheimer's and Huntington's Disease. J Int Neuropsychol Soc 24:833-841
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Fong, Lauren K; Yang, Max M; Dos Santos Chaves, Rodrigo et al. (2018) Full-length amyloid precursor protein regulates lipoprotein metabolism and amyloid-? clearance in human astrocytes. J Biol Chem 293:11341-11357
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Spencer, Brian; Brüschweiler, Sven; Sealey-Cardona, Marco et al. (2018) Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69-87

Showing the most recent 10 out of 914 publications